To further explore the molecular mechanism through which TRIP13 activates the AKT/mTOR pathway, mass spectrometry (MS) was performed to find potential TRIP13-binding proteins in two HCC cell lines. The gene discussed is AKT1; the disease is hepatocellular carcinoma.